One latest research of donor-derived CD7 CAR-T cells in patients with R/R T-ALL reported that the ORR was 95% (95% CI, 76.4 to 99.1) after a median follow-up time of 27.0 months, with 85% (17/20 patients) achieved CR. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.